Author

Masahiko Miyashiro

Institution: Johnson & Johnson K.K. (Japan)

Observed institutions: Janssen Pharmaceutical K.K. (Japan), Johnson & Johnson K.K. (Japan)

ORCID: 0000-0002-3072-3539

Observed ORCID: 0000-0002-3072-3539

OpenAlex ID: A5088232616

A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan

2023 · Masahiko Miyashiro, Yutaka Ishii, et al. · Rheumatology and Therapy · 6

Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study

2024 · Masahiko Miyashiro, Teita Asano, et al. · Drugs - Real World Outcomes · 5

Assessing T-Cell Profile Shifts through IL-23 Inhibition by Guselkumab on Psoriasis

2025 · Yoshifumi Kanayama, Oki Watanabe, et al. · JID Innovations · 1

Works count: 3

Citation count: 12

H-index: 2

I10-index: